Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders.

Autor: Lake DF; Arizona State University, School of Life Sciences, Tempe, AZ USA., Roeder AJ; Arizona State University, School of Life Sciences, Tempe, AZ USA., Gonzalez-Moa MJ; AXIM Biotechnologies, San Diego, CA USA., Koehler M; Arizona State University, School of Life Sciences, Tempe, AZ USA., Kaleta E; Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, Scottsdale, AZ USA., Jasbi P; Arizona State University, College of Health Solutions, Phoenix, AZ USA., Vanderhoof J; Arizona State University, School of Life Sciences, Tempe, AZ USA., McKechnie D; Arizona State University, School of Life Sciences, Tempe, AZ USA., Forman J; Arizona State University, School of Life Sciences, Tempe, AZ USA., Edwards BA; Arizona State University, School of Life Sciences, Tempe, AZ USA., Seit-Nebi A; AXIM Biotechnologies, San Diego, CA USA., Svarovsky S; AXIM Biotechnologies, San Diego, CA USA.
Jazyk: angličtina
Zdroj: Communications medicine [Commun Med (Lond)] 2022 Jul 11; Vol. 2, pp. 85. Date of Electronic Publication: 2022 Jul 11 (Print Publication: 2022).
DOI: 10.1038/s43856-022-00151-2
Abstrakt: Background: While evaluating COVID-19 vaccine responses using a rapid neutralizing antibody (NAb) test, we observed that 25% of mRNA vaccine recipients did not neutralize >50%. We termed this group "vaccine poor responders" (VPRs). The objective of this study was to determine if individuals who neutralized <50% would remain VPRs, or if a third dose would elicit high levels of NAbs.
Methods: 269 healthy individuals ranging in age from 19 to 80 (Average age = 51; 165 females and 104 males) who received either BNT162b2 (Pfizer) or mRNA-1273 (Moderna) vaccines were evaluated. NAb levels were measured: (i) 2-4 weeks after a second vaccine dose, (ii) 2-4 months after the second dose, (iii) within 1-2 weeks prior to a third dose and (iv) 2-4 weeks after a third mRNA vaccine dose.
Results: Analysis of vaccine recipients reveals that 25% did not neutralize above 50% (Median neutralization = 21%, titers <1:80) within a month after their second dose. Twenty-three of these VPRs obtained a third dose of either BNT162b2 or mRNA-1273 vaccine 1-8 months (average = 5 months) after their second dose. Within a month after their third dose, VPRs show an average 5.4-fold increase in NAb levels (range: 46-99%).
Conclusions: The results suggest that VPRs are not permanently poor responders; they can generate high NAb levels with an additional vaccine dose. Although it is not known what levels of NAbs protect from infection or disease, those in high-risk professions may wish to keep peripheral NAb levels high, limiting infection, and potential transmission.
Competing Interests: Competing interestsCo-authors A.J.R., M.A.K., J.V., D.M., J.F., B.E., E.J.K., and P.J. declare no competing interests. D.F.L., S.S., A.S.-N., and M.G.M. declare the existence of a financial competing interest. D.F.L. and S.S. are co-founders of Sapphire, the research division of AXIM Biotechnologies. S.S., M.G.M,. and A.S.-N. are employed by AXIM. All other authors have no competing interests and no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.
(© The Author(s) 2022.)
Databáze: MEDLINE
Externí odkaz: